Geraldo Augusto Pereira

Mr. Geraldo Augusto Pereira

Chemistry Departament, National Institute for Quality Control in Health (INCQS) - Fiocruz, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
Geraldo Augusto PereiraGeraldo Augusto Pereira
Geraldo Augusto Pereira
DCDouglas Chaves
Douglas Chaves
TSTaynara Monsores e Silva
Taynara Monsores e Silva
RMRaissa Emidio de Araújo Motta
Raissa Emidio de Araújo Motta
ASAdriana Barbosa Rocha da Silva
Adriana Barbosa Rocha da Silva
Tomasz M. KarpinskiTomasz M. Karpinski
Tomasz M. Karpinski
The inappropriate use of antimicrobials, along with environmental conditions, can lead to the emergence of resistant microorganisms. The use of phytopharmaceuticals and herbal medicines has a positive impact and represents a promising alternative. Psidium guajava extracts have been widely reported to have antimicrobial potential; however, studies reporting their activity against resistant bacterial strains are scarce. Because of the emerging resistance, the aim of this study was to analyze the antimicrobial capacity of the aqueous extract of guava leaves against wild-type and resistant bacterial strains. The aqueous extract obtained from the leaves of P. guajava was evaluated by HPLC for the content of total phenolics and tannins, antioxidant activity, and chemical composition. The antimicrobial activity of the extracts was analyzed by the disk diffusion and broth microdilution methods. The results of the chemical analysis of the extracts showed total phenolics content of 17.02 ± 6.87 mg/g of dry extract, total tannin content of 14.09 ± 1.20 mg of tannic acid equivalents/g of dry extract, and moderate antioxidant capacity with an EC50 value of 140 µg/mL. Flavonoids are the major compounds (rutin, hesperidin, and quercetin), followed by phenolic acids. Disk diffusion test results showed the presence of inhibition halos for Gram-positive bacteria (Staphylococcus aureus, sensitive and resistant; Staphylococcus pseudintermedius, sensitive and resistant; and Streptococcus spp., beta-hemolytic), while for Gram-negative bacteria (Escherichia coli, sensitive and resistant), there was no inhibition in the tested concentration range. The Minimal Inhibitory Concentration was 6.8 mg/mL for all Gram-positive strains evaluated. The present study demonstrated the antimicrobial activity of the aqueous extract of P. guajava against sensitive and resistant Gram-positive bacteria. The better antimicrobial activity found in the present study compared with previously reported activity should be highlighted and may be related to the higher concentration of total phenolics present in the tested extract. Moreover, the content of tannins found suggests a species with high quality that produces tannins. These new findings suggest an innovative profile regarding therapeutic resources that can be adopted to combat resistant microbial strains.

1 January 2020 in Anais da Academia Brasileira de Ciências
Verified
Journal Article
Open access
PDF file
MAMelina C.C. Alves
Melina C.C. Alves
DCDouglas Chaves
Douglas Chaves
BBByanca R. Benevenuto
Byanca R. Benevenuto
BFBeatriz O. DE Farias
Beatriz O. DE Farias
SCShana de Mattos de Oliveira Coelho
Shana de Mattos de Oliveira Coelho
YCYara Peluso Cid
Yara Peluso Cid
Periodontal disease is considered the main oral cavity disorder in dogs. Essential oils have the potential for use in the prevention and treatment of oral diseases. The antimicrobial activity of Schinus molle L. essential oil (SMEO) has already been reported. Chitosan, a natural product with antimicrobial activity and good biocompatibility has potential in biodental applications. In this study, we evaluated the in vitro antimicrobial activity of SMEO against bacteria associated with periodontal disease in dogs, developed and evaluated the physicochemical properties of a novel chitosan-based buccal delivery system containing SMEO. SMEO showed antimicrobial activity against Gram positive and Gram negative bacteria associated with canine periodontitis, with MIC values of 750 µg.mL-1 for Staphylococcus spp. and Streptococcus spp, 1000 µg.mL-1 for Corynebacterium spp. and 1250 µg.mL-1 for Pseudomonas spp. All formulations evaluated presented adequate physicochemical properties, good stability, and pH values close to buccal pH (5.0–7.0). Chitosan gel loaded with SMEO showed potential as a SMEO delivery system, having the ideal physicochemical and rheological properties (pseudoplastic and apparent viscosities) required for application on buccal tissue. Thus, we can conclude that formulation has the potential to be used for buccal mucosa delivery in the prevention and treatment of periodontal disease in dogs.

31 July 2021 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
GSGabriela Carmelinda Martins dos Santos
Gabriela Carmelinda Martins dos Santos
FSFabio Barbour Scott
Fabio Barbour Scott
DCDiefrey Ribeiro Campos
Diefrey Ribeiro Campos
VMViviane de Sousa Magalhães
Viviane de Sousa Magalhães
DBDebora Azevedo Borges
Debora Azevedo Borges
YCYara Peluso Cid
Yara Peluso Cid

1 January 2021 in Brazilian Journal of Veterinary Medicine
Verified
Journal Article
Open access
PDF file
MLMonique Moraes Lambert
Monique Moraes Lambert
DCDouglas Siqueira de Almeida Chaves
Douglas Siqueira de Almeida Chaves
BABarbara Rauta de Avelar
Barbara Rauta de Avelar
DCDiefrey Ribeiro Campos
Diefrey Ribeiro Campos
DBDebora Azevedo Borges
Debora Azevedo Borges
KCKatherina Coumendouros
Katherina Coumendouros
Plant extracts and essential oils have been showing potential for use as acaricides. Rhipicephalus sanguineus, the brown tick, mainly parasitizes dogs and is responsible for pathogens transmission. The insecticidal and acaricidal activity of the essential oil (EO) of Syzygium aromaticum and eugenol have already been reported, however the activity against R. sanguineus is lacked. To evaluate the acaricidal activity of S. aromaticum EO and eugenol against larvae of R. sanguineus, in vitro assays were performed using the larval immersion test. Bioassays were performed in duplicate, within the concentration range of 0.078 to 40 mg.mL-1. Mortality assessment was performed after 24 hours. Mortality above 90% was achieved through using the EO and eugenol at concentrations greater than 5 and 10 mg.mL-1, respectively. The LC50 values of 1.4 and 3.3 mg.mL-1 for eugenol and S. aromaticum EO, respectively, while the LC90 values found for eugenol and S. aromaticum EO were, respectively, 6.4 and 6.7 mg.mL-1 were calculated. These compounds present activity against R. sanguineus larvae and demonstrate potential for use as acaricides. Extratos vegetais e óleos essenciais têm apresentado potencial para uso como acaricidas. Rhipicephalus sanguineus, o carrapato marrom, parasita principalmente cães, sendo responsável pela transmissão de patógenos. O óleo essencial (OE) de Syzygium aromaticum e o eugenol já tiveram atividade inseticida e acaricida relatada, porém faltam ensaios que relatem atividade contra R. sanguineus. Com o objetivo de avaliar atividade carrapaticida de OE de S. aromaticum e eugenol frente a larvas de R. sanguineus, foram realizados ensaios in vitro por meio de Teste de Imersão Larval. Os bioensaios foram realizados em duplicata, na faixa de concentração de 0,078 a 40 mg.mL-1. A avaliação da mortalidade foi realizada após 24 horas. Mortalidade acima de 90% foi alcançada para o OE e o eugenol em concentrações superiores a 5 e 10 mg.mL-1, respectivamente. Valores de CL50 de 1,4 e 3,3 mg.mL-1 para eugenol e OE de S. aromaticum, respectivamente, enquanto os valores de CL90 encontrados para eugenol e óleo essencial de S. aromaticum foram, respectivamente, de 6,4 e 6,7 mg.mL-1. Os compostos têm atividade contra larvas de R. sanguineus e demonstram potencial para uso como acaricida.

1 January 2021 in Brazilian Journal of Veterinary Medicine
Verified
Journal Article
Open access
PDF file
ILIsabela de Paula Lima
Isabela de Paula Lima
VMViviane de Souza Magalhães
Viviane de Souza Magalhães
RORodrigo Machado de Oliveira
Rodrigo Machado de Oliveira
TFThais Paes Ferreira
Thais Paes Ferreira
GSGabriela Carmelinda Martins dos Santos
Gabriela Carmelinda Martins dos Santos
YCYara `Peluso Cid
Yara `Peluso Cid
Doxycycline (DOX) is the antibiotic of choice for the treatment of canine monocytic ehrlichiosis (CME), one of the main infectious diseases affecting dogs. Despite the therapeutic simplicity, the need for long-term use of DOX tablets (28 days) and gastrointestinal effects may pose problems. The aim of the study was to develop a DOX chewable tablet, evaluate its palatability and pharmacokinetic profile in comparison with a commercial formulation, Doxifin®, and evaluate the influence of co-administration with vitamin supplement on the bioavailability of doxycycline. The AUC0-t values found for DOX chewable tablets (13.85 ± 3.81 μg.h/mL) and Doxifin® (15.88 ± 4.38 μg.h/mL) did not differ significantly (p<0.05). The co-administration of the vitamin supplement Hemolitan® influenced the pharmacokinetic profile of DOX, leading to a decrease in bioavailability for chewable DOX tablets and Doxifin®, with relative bioavailability values (F) of 64% and 62%, respectively. Palatability evaluations confirmed the palatability of the chewable tablets. Therefore, a DOX chewable tablet is an important alternative that can overcome some of the challenges associated with the characteristic bitter taste of doxycycline, with considerable reduction animal stress, and with plasma doxycycline concentrations equivalent in practical terms to a conventional product. A doxiciclina (DOX) é o antibiótico escolhido para o tratamento da erliquiose monocítica canina (EMC), uma das principais doenças infecciosas que afetam os cães. Apesar da simplicidade terapêutica, a necessidade do uso prolongado de comprimidos de DOX (28 dias) e os efeitos gastrointestinais podem representar problemas. O objetivo do estudo foi desenvolver um comprimido para mastigar de DOX, avaliar sua palatabilidade e perfil farmacocinético em comparação com uma formulação comercial, Doxifin®, e avaliar a influência da coadministração com suplemento vitamínico na biodisponibilidade da doxiciclina. Os valores de AUC0-t encontrados para comprimidos mastigáveis de DOX (13,85 ± 3,81 μg.h/mL) e Doxifin® (15,88 ± 4,38 μg.h/mL) não diferiram significativamente (p<0,05). A coadministração do suplemento vitamínico Hemolitan® influenciou o perfil farmacocinético, levando a uma diminuição da biodisponibilidade para comprimidos mastigáveis de DOX e Doxifin®, com valores de biodisponibilidade relativa (F) de 64% e 62%, respectivamente. As avaliações da palatabilidade confirmaram que os comprimidos mastigáveis são palatáveis. Portanto, um comprimido para mastigar de DOX é uma alternativa importante que pode superar alguns dos desafios associados ao sabor amargo característico da doxiciclina, com considerável redução do estresse animal e com concentrações plasmáticas de doxiciclina equivalentes em termos práticos a um produto convencional.